BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses

Summary This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer‐BioNTech) COVID‐19 vaccine booster in 44 B‐cell non‐Hodgkin lymphoma (B‐NHL) patients who failed to respond to two prior doses [42 previously exposed to anti‐CD20 monoclonal antibodies (moAbs) including 13...

Full description

Saved in:
Bibliographic Details
Published in:British Journal of Haematology 2022-03, Vol.196 (6), p.1329-1333
Main Authors: Avivi, Irit, Luttwak, Efrat, Saiag, Esther, Halperin, Tami, Haberman, Shira, Sarig, Ariel, Levi, Sivan, Aharon, Anat, Herishanu, Yair, Perry, Chava
Format: Article
Language:English
Subjects:
BNT162 Vaccine
BNT162b2
B‐cell non‐Hodgkin lymphoma
CD20 antigen
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
COVID‐19 vaccine booster
Hematology
Humans
humoral response
Immunization, Secondary
Lymphoma
Lymphoma, Non-Hodgkin - therapy
Monoclonal antibodies
mRNA
Non-Hodgkin's lymphoma
Patients
Prospective Studies
RNA, Messenger
SARS-CoV-2
Seroconversion
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4169-9398a2d6fc21bafa8910f1f3af05bb4f387bcb9ed315152972a75405d7e5e1413
cites cdi_FETCH-LOGICAL-c4169-9398a2d6fc21bafa8910f1f3af05bb4f387bcb9ed315152972a75405d7e5e1413
container_end_page 1333
container_issue 6
container_start_page 1329
container_title British Journal of Haematology
container_volume 196
creator Avivi, Irit
Luttwak, Efrat
Saiag, Esther
Halperin, Tami
Haberman, Shira
Sarig, Ariel
Levi, Sivan
Aharon, Anat
Herishanu, Yair
Perry, Chava
description Summary This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer‐BioNTech) COVID‐19 vaccine booster in 44 B‐cell non‐Hodgkin lymphoma (B‐NHL) patients who failed to respond to two prior doses [42 previously exposed to anti‐CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients. Longer time from last anti‐CD20 moAb (>6 months) and diagnosis of aggressive lymphoma compared to other, incurable B‐NHLs were associated with increased seroconversion rates (47.8% vs.10.5%, p = 0.019 and 50% vs. 17.9%, p = 0.025 respectively). Thus, seronegative patients with B‐NHL that completed anti‐CD20 therapy more than 6 months prior to the booster have greater chances to achieve seroconversion.
doi_str_mv 10.1111/bjh.18029
format article
fullrecord <record><control><sourceid>proquest_COVID</sourceid><recordid>TN_cdi_proquest_miscellaneous_2622656575</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2622736989</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4169-9398a2d6fc21bafa8910f1f3af05bb4f387bcb9ed315152972a75405d7e5e1413</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS1ERaeFBS-ALLGhi7S-dpzEy87wM62qVkKFbWQ7NpMhsYOddDQ7HoFX4NV4krqdtgsk8OZeWZ_P9T0HoddAjiGdE7VeHUNFqHiGZsAKnlHI4TmaEULKDEhe7aODGNeEACMcXqB9xknJC8Zn6Pf88hoKqijuP1-e4sXV17P3f37-AoFvpNatM1h5H0cTcOuaSZuIowlee3djQmy9S9d4kGNr3Bjxph1XeJ6ea9N12HmX2qVvvn1PULfth5XvJd6sPLay7UyDR4-DiYN39-248XgIrQ9PoxsfTXyJ9qzsonn1UA_Rl48frhfL7OLq09ni9CLTORQiE0xUkjaF1RSUtLISQCxYJi3hSuWWVaXSSpiGAQdORUllyXPCm9Jwk-xih-jdTncI_sdk4lj3bbxbRDrjp1jTgtKCF7zkCX37F7r2U3Dpd4nKCaO8Avp_itKSFaISiTraUTr4GIOxdfKgl2FbA6nv0q1TuvV9uol986A4qd40T-RjnAk42QGb5O_230r1_Hy5k7wFuDuwEQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2622736989</pqid></control><display><type>article</type><title>BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses</title><source>Coronavirus Research Database</source><creator>Avivi, Irit ; Luttwak, Efrat ; Saiag, Esther ; Halperin, Tami ; Haberman, Shira ; Sarig, Ariel ; Levi, Sivan ; Aharon, Anat ; Herishanu, Yair ; Perry, Chava</creator><creatorcontrib>Avivi, Irit ; Luttwak, Efrat ; Saiag, Esther ; Halperin, Tami ; Haberman, Shira ; Sarig, Ariel ; Levi, Sivan ; Aharon, Anat ; Herishanu, Yair ; Perry, Chava</creatorcontrib><description>Summary This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer‐BioNTech) COVID‐19 vaccine booster in 44 B‐cell non‐Hodgkin lymphoma (B‐NHL) patients who failed to respond to two prior doses [42 previously exposed to anti‐CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients. Longer time from last anti‐CD20 moAb (&gt;6 months) and diagnosis of aggressive lymphoma compared to other, incurable B‐NHLs were associated with increased seroconversion rates (47.8% vs.10.5%, p = 0.019 and 50% vs. 17.9%, p = 0.025 respectively). Thus, seronegative patients with B‐NHL that completed anti‐CD20 therapy more than 6 months prior to the booster have greater chances to achieve seroconversion.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.18029</identifier><identifier>PMID: 35075635</identifier><language>eng</language><publisher>England: John Wiley &amp; Sons, Inc</publisher><subject>BNT162 Vaccine ; BNT162b2 ; B‐cell non‐Hodgkin lymphoma ; CD20 antigen ; COVID-19 ; COVID-19 - prevention &amp; control ; COVID-19 Vaccines ; COVID‐19 vaccine booster ; Hematology ; Humans ; humoral response ; Immunization, Secondary ; Lymphoma ; Lymphoma, Non-Hodgkin - therapy ; Monoclonal antibodies ; mRNA ; Non-Hodgkin's lymphoma ; Patients ; Prospective Studies ; RNA, Messenger ; SARS-CoV-2 ; Seroconversion ; Vaccines</subject><ispartof>British Journal of Haematology, 2022-03, Vol.196 (6), p.1329-1333</ispartof><rights>2022 British Society for Haematology and John Wiley &amp; Sons Ltd.</rights><rights>2022. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://novel-coronavirus.onlinelibrary.wiley.com</rights><rights>2022 British Society for Haematology and John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4169-9398a2d6fc21bafa8910f1f3af05bb4f387bcb9ed315152972a75405d7e5e1413</citedby><cites>FETCH-LOGICAL-c4169-9398a2d6fc21bafa8910f1f3af05bb4f387bcb9ed315152972a75405d7e5e1413</cites><orcidid>0000-0002-7864-0089 ; 0000-0003-0212-2135</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2622736989?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,38514,43893</link.rule.ids><linktorsrc>$$Uhttps://www.proquest.com/docview/2622736989?pq-origsite=primo$$EView_record_in_ProQuest$$FView_record_in_$$GProQuest</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35075635$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Avivi, Irit</creatorcontrib><creatorcontrib>Luttwak, Efrat</creatorcontrib><creatorcontrib>Saiag, Esther</creatorcontrib><creatorcontrib>Halperin, Tami</creatorcontrib><creatorcontrib>Haberman, Shira</creatorcontrib><creatorcontrib>Sarig, Ariel</creatorcontrib><creatorcontrib>Levi, Sivan</creatorcontrib><creatorcontrib>Aharon, Anat</creatorcontrib><creatorcontrib>Herishanu, Yair</creatorcontrib><creatorcontrib>Perry, Chava</creatorcontrib><title>BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses</title><title>British Journal of Haematology</title><addtitle>Br J Haematol</addtitle><description>Summary This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer‐BioNTech) COVID‐19 vaccine booster in 44 B‐cell non‐Hodgkin lymphoma (B‐NHL) patients who failed to respond to two prior doses [42 previously exposed to anti‐CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients. Longer time from last anti‐CD20 moAb (&gt;6 months) and diagnosis of aggressive lymphoma compared to other, incurable B‐NHLs were associated with increased seroconversion rates (47.8% vs.10.5%, p = 0.019 and 50% vs. 17.9%, p = 0.025 respectively). Thus, seronegative patients with B‐NHL that completed anti‐CD20 therapy more than 6 months prior to the booster have greater chances to achieve seroconversion.</description><subject>BNT162 Vaccine</subject><subject>BNT162b2</subject><subject>B‐cell non‐Hodgkin lymphoma</subject><subject>CD20 antigen</subject><subject>COVID-19</subject><subject>COVID-19 - prevention &amp; control</subject><subject>COVID-19 Vaccines</subject><subject>COVID‐19 vaccine booster</subject><subject>Hematology</subject><subject>Humans</subject><subject>humoral response</subject><subject>Immunization, Secondary</subject><subject>Lymphoma</subject><subject>Lymphoma, Non-Hodgkin - therapy</subject><subject>Monoclonal antibodies</subject><subject>mRNA</subject><subject>Non-Hodgkin's lymphoma</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>RNA, Messenger</subject><subject>SARS-CoV-2</subject><subject>Seroconversion</subject><subject>Vaccines</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><recordid>eNp9kc1u1DAUhS1ERaeFBS-ALLGhi7S-dpzEy87wM62qVkKFbWQ7NpMhsYOddDQ7HoFX4NV4krqdtgsk8OZeWZ_P9T0HoddAjiGdE7VeHUNFqHiGZsAKnlHI4TmaEULKDEhe7aODGNeEACMcXqB9xknJC8Zn6Pf88hoKqijuP1-e4sXV17P3f37-AoFvpNatM1h5H0cTcOuaSZuIowlee3djQmy9S9d4kGNr3Bjxph1XeJ6ea9N12HmX2qVvvn1PULfth5XvJd6sPLay7UyDR4-DiYN39-248XgIrQ9PoxsfTXyJ9qzsonn1UA_Rl48frhfL7OLq09ni9CLTORQiE0xUkjaF1RSUtLISQCxYJi3hSuWWVaXSSpiGAQdORUllyXPCm9Jwk-xih-jdTncI_sdk4lj3bbxbRDrjp1jTgtKCF7zkCX37F7r2U3Dpd4nKCaO8Avp_itKSFaISiTraUTr4GIOxdfKgl2FbA6nv0q1TuvV9uol986A4qd40T-RjnAk42QGb5O_230r1_Hy5k7wFuDuwEQ</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Avivi, Irit</creator><creator>Luttwak, Efrat</creator><creator>Saiag, Esther</creator><creator>Halperin, Tami</creator><creator>Haberman, Shira</creator><creator>Sarig, Ariel</creator><creator>Levi, Sivan</creator><creator>Aharon, Anat</creator><creator>Herishanu, Yair</creator><creator>Perry, Chava</creator><general>John Wiley &amp; Sons, Inc</general><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>COVID</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7864-0089</orcidid><orcidid>https://orcid.org/0000-0003-0212-2135</orcidid></search><sort><creationdate>202203</creationdate><title>BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses</title><author>Avivi, Irit ; Luttwak, Efrat ; Saiag, Esther ; Halperin, Tami ; Haberman, Shira ; Sarig, Ariel ; Levi, Sivan ; Aharon, Anat ; Herishanu, Yair ; Perry, Chava</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4169-9398a2d6fc21bafa8910f1f3af05bb4f387bcb9ed315152972a75405d7e5e1413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>BNT162 Vaccine</topic><topic>BNT162b2</topic><topic>B‐cell non‐Hodgkin lymphoma</topic><topic>CD20 antigen</topic><topic>COVID-19</topic><topic>COVID-19 - prevention &amp; control</topic><topic>COVID-19 Vaccines</topic><topic>COVID‐19 vaccine booster</topic><topic>Hematology</topic><topic>Humans</topic><topic>humoral response</topic><topic>Immunization, Secondary</topic><topic>Lymphoma</topic><topic>Lymphoma, Non-Hodgkin - therapy</topic><topic>Monoclonal antibodies</topic><topic>mRNA</topic><topic>Non-Hodgkin's lymphoma</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>RNA, Messenger</topic><topic>SARS-CoV-2</topic><topic>Seroconversion</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Avivi, Irit</creatorcontrib><creatorcontrib>Luttwak, Efrat</creatorcontrib><creatorcontrib>Saiag, Esther</creatorcontrib><creatorcontrib>Halperin, Tami</creatorcontrib><creatorcontrib>Haberman, Shira</creatorcontrib><creatorcontrib>Sarig, Ariel</creatorcontrib><creatorcontrib>Levi, Sivan</creatorcontrib><creatorcontrib>Aharon, Anat</creatorcontrib><creatorcontrib>Herishanu, Yair</creatorcontrib><creatorcontrib>Perry, Chava</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Coronavirus Research Database</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British Journal of Haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Avivi, Irit</au><au>Luttwak, Efrat</au><au>Saiag, Esther</au><au>Halperin, Tami</au><au>Haberman, Shira</au><au>Sarig, Ariel</au><au>Levi, Sivan</au><au>Aharon, Anat</au><au>Herishanu, Yair</au><au>Perry, Chava</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses</atitle><jtitle>British Journal of Haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2022-03</date><risdate>2022</risdate><volume>196</volume><issue>6</issue><spage>1329</spage><epage>1333</epage><pages>1329-1333</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary This prospective study evaluated seroconversion rates in response to BNT162b2 (Pfizer‐BioNTech) COVID‐19 vaccine booster in 44 B‐cell non‐Hodgkin lymphoma (B‐NHL) patients who failed to respond to two prior doses [42 previously exposed to anti‐CD20 monoclonal antibodies (moAbs) including 13 under maintenance treatment]. Seroconversion was obtained in 29.5% of the patients. Longer time from last anti‐CD20 moAb (&gt;6 months) and diagnosis of aggressive lymphoma compared to other, incurable B‐NHLs were associated with increased seroconversion rates (47.8% vs.10.5%, p = 0.019 and 50% vs. 17.9%, p = 0.025 respectively). Thus, seronegative patients with B‐NHL that completed anti‐CD20 therapy more than 6 months prior to the booster have greater chances to achieve seroconversion.</abstract><cop>England</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>35075635</pmid><doi>10.1111/bjh.18029</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-7864-0089</orcidid><orcidid>https://orcid.org/0000-0003-0212-2135</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 0007-1048
ispartof British Journal of Haematology, 2022-03, Vol.196 (6), p.1329-1333
issn 0007-1048
1365-2141
language eng
recordid cdi_proquest_miscellaneous_2622656575
source Coronavirus Research Database
subjects BNT162 Vaccine
BNT162b2
B‐cell non‐Hodgkin lymphoma
CD20 antigen
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
COVID‐19 vaccine booster
Hematology
Humans
humoral response
Immunization, Secondary
Lymphoma
Lymphoma, Non-Hodgkin - therapy
Monoclonal antibodies
mRNA
Non-Hodgkin's lymphoma
Patients
Prospective Studies
RNA, Messenger
SARS-CoV-2
Seroconversion
Vaccines
title BNT162b2 mRNA COVID‐19 vaccine booster induces seroconversion in patients with B‐cell non‐Hodgkin lymphoma who failed to respond to two prior vaccine doses
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T12%3A54%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_COVID&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BNT162b2%20mRNA%20COVID%E2%80%9019%20vaccine%20booster%20induces%20seroconversion%20in%20patients%20with%20B%E2%80%90cell%20non%E2%80%90Hodgkin%20lymphoma%20who%20failed%20to%20respond%20to%20two%20prior%20vaccine%20doses&rft.jtitle=British%20Journal%20of%20Haematology&rft.au=Avivi,%20Irit&rft.date=2022-03&rft.volume=196&rft.issue=6&rft.spage=1329&rft.epage=1333&rft.pages=1329-1333&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.18029&rft_dat=%3Cproquest_COVID%3E2622736989%3C/proquest_COVID%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4169-9398a2d6fc21bafa8910f1f3af05bb4f387bcb9ed315152972a75405d7e5e1413%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2622736989&rft_id=info:pmid/35075635&rfr_iscdi=true